Streamlining development and assessment of biosimilar medicines

EMA is exploring improvements to the development and evaluation of biosimilar medicines, while upholding strict European Union (EU) safety standards. With over two decades of…

Leave a Reply

Your email address will not be published. Required fields are marked *